Through centrality analysis, 4 of the top 10 hub proteins, which were not found or only found in one target database, were considered as novel valid therapeutic targets (FANCD2 and NCOA4 for COAD, IKBKB for GBM, and RHOA for GBM and SCLC) [133]. This evidence concerns the gene NCOA4 and glioblastoma.